

Bibliographie Cannabinoïdes et Epilepsie

Docteur Christian SUEUR, GRECC, septembre 2018.

1. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (*Medicinal cannabis*) in Mexican Children with refractory Epilepsy, *Hindawi, Neurology Research International*, 2017, ID 2985729, 5 p.
2. American Academy of Neurology : Medical marijuana liquid extract may bring hope for children with severe epilepsy, *American Academy of Neurology Press*, 2015.
<https://www.aan.com/PressRoom/Home/PressRelease/1364>
3. AMES F.R., CRIDLAND S. : Anticonvulsant effect of cannabidiol, *South Africa Medical Journal*, 1986, 69, 1, 14.
4. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, www.medscape.com/viewarticle/860357_print, 2016
5. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there a potential treatment role in epilepsy ?, *Expert Opin Pharmacother*, 2015, 16, 13, 1911-1914.
6. **BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Endocannabinoids and epilepsy, Chapter 6, *Cannabinoids in Neurologic and Mental Disease*, Academic Press, 2015, 125-172.**
7. BRIAN P.G., SCOTT C.B. : Animal models in epilepsy research : legacies and new directions, *Nat Neurosciences*, 2015, 18, 339-343.
8. CARLINI E.A., CUNHA J.M. : Hypnotic and antiepileptic effects of cannabidiol, *J Clin Pharmacol*, 1981, 21, 417-427.
9. CHEN K.A., FARRAR M., CARDAMONE M., GILL D. et al. : Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience, *Medical Journal of Australia*, 2018 August 13.
10. CHIU P., OLSEN D.M., BORYS H.K. et al : The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats, *Epilepsia*, 1979, 20, 365-375.
11. CILIO M.R., THIELE E.A., DEVINSKY O. : The case for assessing cannabidiol in epilepsy, *Epilepsia*, 2014, 55, 6, 787-790.
12. CITRARO R., RUSSO E., De SARRO G. et al. : CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations, *Epilepsy Research*, 2013, 106, 1-2, 74-82.
13. CONSROE P.F., WOOD G.C., BUCHSBAUM H. : Anticonvulsant nature of marihuana smoking, *JAMA*, 1975, 234, 3, 306-307.
14. CONSROE P.F., WOLKIN A. : Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats, *J Pharmacol Exp Ther*, 1977, 201, 1, 26-32.
15. CONSROE P.F., MARTIN A., SINGH V. : Antiepileptic potential of cannabidiol analogs, *J Clin Pharmacol*, 1981, 21, 8-9, 428-436.
16. CONSROE P.F. : Brain Cannabinoid systems as targets for the therapy of neurological disorders, *Neurobiological Diseases*, 1998, 5, 534-541.
17. CUNHA J.M., CARLINI E.A., MECHOULAM R. et al. : Chronic administration of cannabidiol to healthy volunteers and epileptic patients, *Pharmacology*, 1980, 21, 3, 175-185.

18. DETYNIECHI K., LAWRENCE H. : Marijuana use in epilepsy : the myth and the reality, *Curr Neurol Neurosci Rep*, 2015, 15, 65.
19. DETYNIECKI K., HIRSCH L.J. : Cannabidiol for epilepsy : trying to see through the haze, *The Lancet*, 2016, 15, 3, 235-237.
20. DEVINSKY O., VICKREY B.G., CRAMER J. et al. : Development of the quality of life in epilepsy inventory, *Epilepsia*, 1995, 36, 1089-1104.
21. DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, *Epilepsia*, 2014, 55, 6, 791-802.
22. DEVINSKY O. : Commentary : Medical Marijuana survey & Epilepsy, *Epilepsia*, 2015, 56, 1, 7-8.
23. DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label intervention trial, *Lancet Neurology*, 2015.
24. DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug -Resistant Seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 21, 2011-2020.
25. Di MARZO V. : The endocannabinoid system : its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation, *Pharmacological Research*, 2009, 60, 2, 77-84.
26. Dos SANTOS R.G., HALLAK J.E., LEITE J.P., ZUARDI A.W., CRIPPA J.A. : Phytocannabinoids and epilepsy, *Journal of Clinical Pharm Ther*, 2015, 40, 2, 135-143.
27. EDWARDS M., PAIGE F. : The case for medical marijuana in epilepsy, *Epilepsia*, 2014, 55, 6, 783-786.
28. ELLISON J.M., GELWAN E., OGLETREE J. : Complex partial seizure symptoms affected by marijuana abuse, *Journal of Clinical Psychiatry*, 1990, 51, 439-440.
29. FEENEY D.M. : Marijuana Use Among Epileptics, *JAMA*, 1976, 235, 11, 1105.
30. FEENEY D.M. : Marijuana and Epilepsy : paradoxical anticonvulsant effects, Advanced Biosciences, 1978, 22/23, 643-657.
31. FEZZA F., MARRONE M.C., MACCARRONE M., MARINELLI S. : Distinct modulation of the endocannabinoid system upon Kainic Acid-induced invivo seizures and in vitro epileptiform bursting, *Molecular and Cellular Neuroscience*, 2014, 62, 1-9.
32. FLOREK- LUSCZKI M., ZAGAJA M., LUSCZKI J.J. : Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock- induced seizure model and chimney test in mice, *Epilepsy Research*, 2014, 108, 10, 1728-1733.
33. FLOREK- LUSCZKI M., ZAGAJA M., LUSCZKI J.J. : Influence of arachidonyl-20-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute sid-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimney test in mice, *Fundam Clin Pharmacol*, 2015, 29, 382-393.
34. FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand access program, *Annual Meeting of the American Epilepsy Society, Seattle, December 5-9, 2014*, Abstract.
35. FRIEDMAN D., DEVINSKY O. : Cannabinoids in the Treatment of Epilepsy, *New England Journal of Medicine*, 2015, 373, 1048-1058.

36. GORDON E., DEVINSKY O. : Alcohol and Marijuana : Effects on Epilepsy and Use by Patients, *Epilepsia*, 2001, 42, 10, 1266-1272.
- 37. GLOSS D., VICKREY B. : Cannabinoids for epilepsy, Cochrane Database Systematic Review, 2012, 6.**
38. GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, *Journal of Child Neurology*, 2016.
39. GROSS D.W., HAMM J., ASHWORTH N.L. et al. : Marijuana use and epilepsy : prevalence in patients of a tertiary care epilepsy center, *Neurology*, 200', 62, 2095-2097.
40. GUGGENHUBER S., MONORY K., LUTZ B., KLUGMANN M.M. : AAV vector-mediated overexpression of CB1 cannabinoid receptor on pyramidal neurons of the hippocampus protects against seizure-induced excitotoxicity, *PloS One*, 2010, 5, 12, 15707.
41. GUY G., WRIGHT S., MEAD A., DEVINSKY O. : Use of Cannabinoids in the treatment of Epilepsy, 2015, *Patent Application Pub : US 2016/0166515 A1*, GW Pharma Limited, Cambridge, (GB), June 2016.
42. HAUSMAN-KEDEM M., MENASCU S., KRAMER U. : Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, *Brains & Development*, 2018, in press.
43. HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, *Epilepsy & Behavior*, 2012, 25, 4, 563-566.
- 44. HILL A.J., HILL T.D.M., WHALLEY B.J. : The Development of Cannabinoid Based Therapies for Epilepsy, *Molecular, Pharmacological, Behavioral and Clinical Feature*, 2013, 164-24.**
45. HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, *Epilepsy & Behaviour*, 2015, 47, 138-141.
46. JOHNSON D.D., McNEILL J.R., CRAWFORD R.D. et al. : Epileptiform seizures in domestic fowl. The anticonvulsant activity of delta 9-tetrahydrocannabinol, *Can J Physiol Pharmacol*, 1975, 53, 439-448.
47. JONES et al. : Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures, *Seizures*, 2012, 21, 5, 344-352.
- 48. KALKACH-APARICIO M., CUELLAR-HERRERA M., FLORES-RAMIREZ E.L. et al. : The use of cannabis as an antiepileptic treatment in Mexico : A review, bioethical analysis, discussion and position of the Hospital General de Mexico, Epilepsy Clinic, Revista Médical del Hospital General de Mexico, 2016, 11 p.**
49. KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, *Pediatr Neurol*, 2017, 71, 18-23.
50. KARANIAN D.A., KARIM S.L., WOOD J.T., WILLIAMS J.S., et al. : Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage, *J Pharmacol Exp Ther*, 2007, 322, 3, 1059-1066.
51. KATONA I. : Cannabis and Endocannabinoid Signaling in Epilepsy, *Handbook of Experimental Pharmacology*, 2015, 231, 285-316.

52. KOO C.M., KANG H.-C. : Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, *Journal of Epilepsy Research*, 2017, 7, 1, 1-5.
53. KWAN P., ARZIMANOGLOU A., BERG A.T. et al. : Definition of drug resistant epilepsy : Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, *Epilepsia*, 2010, 51, 6, 1069-1077.
54. LADINO L.D., HERANDEZ-RONQUILLO L., TELLEZ-ZENTENO J.F. : Medical marijuana for epilepsy : a case series, *Can J Neurol Sci*, 2014, 41, 753-758.
55. LEO A., RUSSO E., ELIA M. : Cannabidiol and epilepsy : Rationale and therapeutic potential, *Pharmacological Research*, 2016, 107, 85-92.
56. LIPPIELLO P., BALESTRINI S., CITRARO R., RUSSO E. et al. : From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We, *Curr Pharm Des*, 2016, 22, 42, 6426-6433.
57. LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, *New England Journal of Medicine*, 2015, 373 1048-1058.
58. LORENZ R. : On the application of cannabis in paediatrics and epileptology, *Neuroendocrinol Lett*, 2004, 25, 1-2, 40-44.
59. LUTZ B. : On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures, *Biochemical Pharmacology*, 2004, 68, 1691-1698.
60. MARSICANO G., GOODENOUGH S., MONORY K., HERMAN H. et al. : CB1 cannabinoid receptors and on-demand defense against excitotoxicity, *Science*, 2003, 302 (5642), 84-88.
61. MARTIN A.R., CONSROE P., SINGH V., MECHOULAM R. et al. : Structure-anticonvulsant activity relationships of cannabidiol analogs, *NIDA Research Monography*, 1987, 79, 48-58.
62. McLACHLAN R.S. : Marijuana : A Time-Honored but Untested Treatment for Epilepsy, *Canadian Journal of Neurological Sciences*, 2015, 42, 2, 88-91.
63. MELDRUM B.S., FARIELLO R.G., PUIL E.A. et al. : Delta 9-tetrahydrocannabinol and epilepsy in the photosensitive baboon Papio papio, *Epilepsia*, 1974, 15, 255-264.
64. MONORY K., MASSA F., EGERTOVA M., EDER M. et al. : The endocannabinoid system controls key epileptogenic circuits in the hippocampus, *Neuron*, 2006, 51, 4, 455-466.
65. MORTATI K., DWORETZKY B., DEVINSKY O. : Marijuana : An Effective Antiepileptic Treatment in Partial Epilepsy ? A Case Report and Review of the Literature, *Reviews in Neurological Diseases*, 2007, 4, 2, 103-106.
66. NAIDOO V., NIKAS S.P., KARANIAN D.A., WOOD J.T. et al. : A new generation fatty acid amide hydrolase inhibitor protects against kaiante-induced excitotoxicity, *Journal of Molecular Neuroscience*, 2011, 43, 3, 493-502.
67. NAIDOO V., KARANIAN D.A., VADIVEL S.K., LOCKLEAR J.R. et al. : Equipotent inhibition of fatty acid amide hydrolase and monacylglycerol lipase – Dual targets of the endocannabinoid system to protect against seizure pathology, *Neurotherapeutics*, 2012.
68. NEALE M. : Efficacy and safety of cannabis for treating children with refractory epilepsy, *Nurs Child Young People*, 2017, 29, 7, 32-37.
69. O'CONNELL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, *Epilepsy & Behavior*, 2016, 8 p.
70. OHRI A., DOUGHERTY M. : Exploring the Use of Cannabidiol in Epilepsy Management, *Practical Neurology*, 2016, July/August, 48-50.

71. OLDHAM M., SULLIVAN J., SINGHAL N., TILTON N., CILIO M. : Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsy, in « Proceedings of the American Epilepsy Society Annual Meeting, 2015, December 4-8, Philadelphia, P.A., Abstr 2.296, *American Epilepsy Society*, Chicago, Il.
72. PATI S, ALEXOPOULOS A.V. : Pharmacoresistant epilepsy : From pathogenesis to current and emerging therapies, *Cleveland Clinic Journal of Medicine*, 2010, 77, 7, 457.
73. PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, *Epilepsy & Behavior*, 2013, 29, 3, 574-577.
74. PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, *Epilepsy & Behavior*, 2015, 45, 49-52.
75. REDDY D.S., GOLUB V.M. : The Pharmacological Basis of Cannabis Therapy for Epilepsy, *J Pharmacol Exp Ther*, 2016, 357, 1, 45-55.
76. REDDY D.S. : The Utility of Cannabidiol in the Treatment of Refractory Epilepsy, *Clin Pharmacol Ther*, 2017, 101, 2, 182-184.
77. REGESTA G., TANGANELLI P. : Clinical aspects and biological bases of drug-resistant epilepsies, *Epilepsy Research*, 1999, 34, 2, 109-122.
- 78. ROSENBERG E.C., TSIEN RW, WHALLEY B.J., DEVINSKY O. : Cannabinoids and Epilepsy, *Neurotherapeutics*, 2015, 18, 747-768. (Cochrane Review)**
79. ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, *Epilepsia*, 2017, 1-5.
80. RUSSO E.B. : Cannabis and epilepsy : An ancient treatment returns to the fore, *Epilepsy & Behavior*, 2016, 6 p.
81. SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, *Pediatr Neurol*, 2015, 52, 5, 544-547.
82. SURAEV A.S., TODD L., BOWEN M.T., ALLSOP D.J. et al. : An Australian nation wide survey on medicinal cannabis use for epilepsy : History of antiepileptic drug treatment predicts medicinal cannabis use, *Epilepsy & Behavior*, 2017, 7 p.
83. SZAFLARSKI J.P., BEBIN E.M. : Cannabis, cannabidiol and epilepsy – From receptors to clinical response, *Epilepsy & Behavior*, 2014, 41, 277-282.
84. SZAFLARSKI J.P., MARTINA BEBIN E., COMI A.M., PATEL A.D. et al. : Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies : Expanded access program results, *Epilepsia*, 2018, 1-9.
85. SZAFLARSKI J.P., MARTINA BEBIN E., CUTTER G., DeWOLF J. et al. : Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study, *Epilepsy & Behavior*, 2018 Aug 9, pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020.
86. TANG R., FANG F. : Trial of Cannabidiol for Drug -Resistant Seizures in the Dravet Syndrome, Comment, *New England Journal of Medicine*, 2017, 377, 7, 699.
87. THIELE E.A., MARSH E.D., FRENCH J.A. et al. – GWPCARE4 Study Group : Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4) : a randomised, double-blind, placebo-controlled phase 3 trial, *The Lancet*, 2018.
88. TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, *Epilepsia*, 2017, 58, 1, 123-127.

89. TREMBLY B., SHERMAN M. : Double -blind clinical study of cannabidiol as a secondary anticonvulsant, in « *Marijuana'90 International Conference on Cannabis and Cannabinoids* », 1990.
90. TURKANIS S.A., SMILEY K.A., BORYS H.K., OLSEN D.M., KARLER R. : An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats, *Epilepsia*, 1979, 20, 4, 351-363.
91. TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, *Seizure*, 2016, 35, 41-44.
92. UPADHYA D., CASTRO O.W., UPADHYA R., SHETTY A.K. : Prospects of cannabidiol for easing Status Epilepticus-Induced Epileptogenesis and related Comorbidities, *Molecular Neurobiology*, 25 January 2018, doi.org/10.1007/s12035-018-0898-y.
93. VEZYROGLOU K., CROSS J.H. : Targeted Treatment in Childhood Epilepsy Syndromes, *Epilepsy, Current treatment Options Neurology*, 2016, 18, 29, 12 pp.
94. WADA J.A., OSAWA T., CORCORAN M.E. : Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons papio papio, *Epilepsia*, 1975, 16, 439-448.
95. WALLACE M.J., BLAIRR.E., FALENSKI K.W., MARTIN B.R., DeLORENZO R.J. : The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy, *J Pharm Exp Ther*, 2003, 307, 129-137.
96. WELTY et al. : Cannabidiol : promise and pitfalls, *Epilepsy Curr*, 2014, 14, 5, 250-252.
97. WONG S.S., WILENS T.E. : Medical Cannabinoids in Children and Adolescents : A Systematic Review, *Pediatric*, 2017, 140, 16 p.

EPIDIOLEX® – Epilepsie de l'enfant

Essais cliniques : DEVINSKY et al. (2014), DEVINSKY et al. (2016), DEVINSKY et al. (2017).

GW Pharmaceutical, NCT02091375. (2015)

- Epidiolex® : 98 % CBD oil.
- Dose 25 à 50 mg/kg/jour.

- ❖ DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, *Epilepsia*, 2014, 55, 6, 791-802.
- ❖ DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, *Lancet Neurology*, 2015.
- ❖ DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 21, 2011-2020.
- ❖ LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, *New England Journal of Medicine*, 2015, 373 1048-1058.
- ❖ O'CONNELL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, *Epilepsy & Behavior*, 2016, 8 p.
- ❖ ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a

- prospective, open-label clinical study with cannabidiol, *Epilepsia*, 2017, 1-5.
- ❖ TANG R., FANG F. : Trial of Cannabidiol for Drug -Resistant Seizures in the Dravet Syndrome, Comment, *New England Journal of Medicine*, 2017, 377, 7, 699.

- GW Pharmaceuticals Initiate second Phase 3 Pivotal Study of Epidiolex (CBD) i Lennox Gastaut Syndrome. *Press Release*, June 11, 2015.

<https://www.gwpharm.com/epilepsy-patients-caregivers/clinicians-researchers>
<https://www.cannabis-medicinale.fr/epidiolex/>

- GW Pharmaceuticals and the Government of New South Wales announce a strategic agreement to study epidiolex and CBDV in a clinical trial and research program for children with epilepsy, *GW Pharma Press Release*, October 17, 2015

[http://www.gwpharm.com/GWPandGovNewSouthWales271015.aspx.](http://www.gwpharm.com/GWPandGovNewSouthWales271015.aspx)

- USA : Use of Cannabinoids in the treatment of Epilepsy, 2015, *Patent Application Pub : US 2016/0166515 A1*, GW Pharma Limited, Cambridge, (GB) : GUY G., WRIGHT S., MEAD A., DEVINSKY O. (June 2016)

Autres essais cliniques :

Essai clinique : TREMBLY B. et SHERMAN M. (1990)

- « no differences between CBD and Placebo »
- faible dose CBD (100 mg once daily)

- ❖ TREMBLY et SHERMAN : Double -blind clinical study of cannabidiol as a secondary anticonvulsant, in « *Marijuana'90 International Conference on Cannabis and Cannabinoids* », 8-11 Juillet 1990, Kolymbari, Crète, IACM.

Essai clinique : Open study, Faculté de Médecine, Università « La Sapienza », 00100 Rome, Italy, (2002) :

- CBD in a 2,5% corn oily

- ❖ PELLICCIA A., GRASSI G., ROMANO A., CROCCHIALO P. : Treatment with CBD in oily solution of drug-resistant paediatric epilepsies, *2005 Congress on Cannabis and the Cannabinoids, Leiden, The Nederlands, Meeting Abstract, IACM*, p 14.

Essai clinique : LORENZ (2004)

- Dronabinol
- Case series (Neurodegenerative diseases, mitochondrialopathy, post-hypoxic state, epilepsy)

- ❖ LORENZ R. : On the application of cannabis in paediatrics and epileptology, *Neuroendocrinol Lett*, 2004, 25, 1-2, 40-44.

Essai clinique : HESS et al. (2011)

- étude de l'efficacité du CBD dans le cadre des épilepsies résistantes dans la Sclérose Tubéreuse Complexé (TSC)

- ❖ HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, *Epilepsy & Behavior*, 2012, 25, 4, 563-566.

Essai clinique : GEDDE et MAA (2013)

- Realm Oil (extract of 16 :1 CBD cannabis plant)
- 4 à 12 mg/kg /jour

Essai clinique : PORTER et JACOBSEN (2013) : étude faite par des parents d'enfants présentant des épilepsies résistantes et prenant régulièrement du cannabis

- CBD-enriched cannabis product
- 19 patients, 16 répondreurs

- ❖ PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, *Epilepsy & Behavior*, 2013, 29, 3, 574-577.

Essai clinique : FRIEDMAN et al. (2014)

- CBD (Epidiolex® 25 mg/kg / jour) + clobazam (17 patients) + group control clobazam (16 patients)
- 7/17 patients ont pu obtenir une réduction de leur dose de clobazam
- ❖ FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand access program, *Annual Meeting of the American Epilepsy Society, Seattle, December 5-9, 2014, Abstract*.

Essai clinique : SAADE et JOSHI (2015)

- MMSI
- CBD Case Report
- ❖ SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, *Pediatr Neurol*, 2015, 52, 5, 544-547.

Essai clinique : HUSSAIN et al. (2015)

- CBD-enriched OCE
- Parent survey

❖ HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, *Epilepsy & Behaviour*, 2015, 47, 138-141.

Essai clinique : PRESS et al. (2015)

- OCE
- Retrospective chart review

❖ PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, *Epilepsy & Behavior*, 2015, 45, 49-52.

Essai clinique : TZADOK et al. (2016)

- CBD-enriched OCE
- Retrospective chart review

❖ TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, *Seizure*, 2016, 35, 41-44.

Essai clinique : TREAT et al. (2017)

- OCE
- Retrospective chart review

❖ TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, *Epilepsia*, 2017, 58, 1, 123-127.

Essai clinique : KAPLAN et al. (2017)

- CBD
- Open-label trial

❖ KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, *Pediatr Neurol*, 2017, 71, 18-23.

Essai clinique : GOFSHTEYN et al. (2017)

- CBD
- Open-label trial

- ❖ GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRE) in the Acute and Chronic Phases, *Journal of Child Neurology*, 2016.